Ken O'Flynn

248. Deputy Ken O'Flynn asked the Minister for Justice, Home Affairs and Migration the number of cases involving the seizure of scrambler bikes or quad bikes that resulted in a prosecution file being prepared by An Garda Síochána in each of the past three years; and if he will make a statement on the matter. [10818/26]

249. Deputy Ken O'Flynn asked the Minister for Justice, Home Affairs and Migration to list the youth diversion or community-based prevention programmes currently in place to address the antisocial use of scrambler bikes and quad bikes; the locations in which these programmes operate; the annual funding allocated; and the Garda divisions where no such programme is currently available. [10819/26]

315. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive has completed, or is in the process of completing, any National Centre for Pharmacoeconomics Rapid Review, Health Technology Assessment, or other formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management; the date on which each assessment commenced; the current stage reached in each case; and the expected month in 2026 in which a pricing and reimbursement decision will be brought to the HSE senior leadership team. [10654/26]

316. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive or her Department has prepared, commissioned, received, or reviewed any cost-effectiveness analysis, budget impact analysis, or economic model relating to the use of GLP-1 receptor agonist medicines for obesity or weight management, including semaglutide and tirzepatide; whether any such analysis includes modelling of downstream cost offsets relating to type 2 diabetes, cardiovascular disease, or related complications; and if so, to provide the title, authoring body, and completion date of each such analysis. [10655/26]

317. Deputy Ken O'Flynn asked the Minister for Health to outline the policy or decision framework used by the Health Service Executive when considering prevention-based outcomes, including reductions in the future incidence of type 2 diabetes and cardiovascular disease, in medicines reimbursement decisions under the Health (Pricing and Supply of Medical Goods) Act 2013; and whether the Department has issued, or intends to issue, policy guidance on how long-term prevention savings are weighted in value-for-money assessments. [10656/26]

318. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken or commissioned any assessment of the equity implications of current access arrangements for GLP-1 receptor agonist medicines for obesity or weight management, including the extent to which access is determined by capacity to pay out of pocket rather than clinical need; and whether the forthcoming national obesity strategy will include policy commitments on equitable access to evidence-based pharmacological treatments for obesity. [10657/26]

319. Deputy Ken O'Flynn asked the Minister for Health to provide the eligibility criteria, prescribing settings, and clinical governance requirements applying to the managed access system under which liraglutide (Saxenda) is reimbursed under the General Medical Services and Drugs Payment Schemes; and to provide the number of patients approved under this pathway in each of the years 2024 and 2025, and to date in 2026. [10658/26]

320. Deputy Ken O'Flynn asked the Minister for Health the current policy position of her Department on whether GLP-1 receptor agonist medicines for obesity or weight management should be eligible for reimbursement under the Drugs Payment Scheme, subject to health technology assessment and clinical governance; whether any policy review is under way in the context of the development of the new national obesity strategy; and the expected publication date of any updated policy position arising. [10659/26]

321. Deputy Ken O'Flynn asked the Minister for Health whether the national obesity strategy currently in development will explicitly address the role of pharmacological treatment for obesity, including eligibility, reimbursement pathways, and equity of access; and whether she will outline how medicines policy is being aligned with the objectives of that strategy. [10660/26]

324. Deputy Ken O'Flynn asked the Minister for Health whether her Department recognises that, for some people with disabilities and people receiving home-care supports, pharmacist-prepared monitored dosage systems, including blister packs, are clinically required to ensure safe medication administration and compliance; whether any national clinical guidance, policy circular, or Department-approved criteria exist to determine when such supports are clinically indicated; and if she will make a statement on the matter. [10668/26]

325. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken, or commissioned, any patient safety or risk assessment regarding the withdrawal or non-funding of pharmacist-prepared blister packs for people with disabilities or cognitive impairment who rely on such supports in a home-care setting; the findings of any such assessment; and if none has been undertaken, when such an assessment will be completed. [10669/26]

326. Deputy Ken O'Flynn asked the Minister for Health whether her Department has carried out a disability impact assessment, equality impact assessment, or human rights analysis in respect of the non-funding of monitored dosage systems, including blister packs, under the long-term Illness scheme; and if she will confirm whether the implications for people with disabilities living independently or with home-care supports were formally considered. [10670/26]

327. Deputy Ken O'Flynn asked the Minister for Health when her Department first became aware that monitored dosage systems, including blister packs, were being provided to patients in practice while pharmacies claimed phased dispensing fees; the policy, governance, or compliance actions that were taken by her Department at that time; and if she will outline the Department’s oversight responsibilities in respect of ensuring patient safety during any subsequent policy or fee changes. [10671/26]

328. Deputy Ken O'Flynn asked the Minister for Health what interim safeguards or guidance have been issued by her Department to ensure that patients with disabilities or complex medication needs do not experience disruption to medication compliance supports during the current pause in changes to phased dispensing arrangements; and whether clinicians or pharmacists have discretion to continue such supports where clinically indicated. [10672/26]

329. Deputy Ken O'Flynn asked the Minister for Health the mechanism that exist, or are being considered, whereby a clinician, pharmacist, or multidisciplinary care team may formally certify that monitored dosage systems, including blister packs, are clinically necessary for an individual patient; and whether such certification would permit continued provision without cost to the patient under existing schemes. [10673/26]

330. Deputy Ken O'Flynn asked the Minister for Health the way in which the non-funding of pharmacist-prepared blister packs aligns with national home-care policy objectives that support independent living for people with disabilities and older persons; and whether her Department accepts that medication compliance supports form an integral part of safe home-based care. [10674/26]

331. Deputy Ken O'Flynn asked the Minister for Health when her Department’s examination of the use of monitored dosage systems, including blister packs, will conclude; whether formal policy proposals will be published; and if she will commit to ensuring that any future framework explicitly addresses the needs of people with disabilities and those receiving home-care supports. [10675/26]

332. Deputy Ken O'Flynn asked the Minister for Health the total number of residential properties currently owned by the Health Service Executive which are vacant; the number deemed surplus to requirements; the length of time each property has been vacant; and if she will make a statement on the matter. [10678/26]

333. Deputy Ken O'Flynn asked the Minister for Health to outline the policy framework governing the retention, disposal, or repurposing of vacant residential properties owned by the Health Service Executive; when this policy was last reviewed; and if she will make a statement on the matter. [10679/26]

334. Deputy Ken O'Flynn asked the Minister for Health the formal engagement that has taken place between his Department, the Department of Housing, Local Government and Heritage, and the Land Development Agency regarding the potential transfer or reuse of vacant HSE-owned residential properties for housing purposes; and if she will make a statement on the matter. [10680/26]

335. Deputy Ken O'Flynn asked the Minister for Health to identify the principal legal, financial, or administrative barriers preventing the timely reuse or disposal of vacant residential properties owned by the Health Service Executive; the steps being taken to address these barriers; and if she will make a statement on the matter. [10681/26]

336. Deputy Ken O'Flynn asked the Minister for Health the annual cost to the State of maintaining vacant residential properties owned by the Health Service Executive, including security, insurance, and maintenance; and if she will make a statement on the matter. [10682/26]

206. Deputy Ken O'Flynn asked the Tánaiste and Minister for Finance if he has approved, or intends to approve, in principle, any policy direction arising from the Revenue Commissioners' consultation on the modernisation of withholding taxes, including professional services withholding tax and relevant contracts tax, that would involve increased reporting frequency or real-time or near-real-time integration between businesses' accounting or financial systems and the Revenue Commissioners; if he is satisfied that such an approach would be proportionate for small and medium-sized enterprises, particularly those operated by non-professional bookkeepers; if a cost-benefit or behavioural impact assessment has been carried out at policy level within his Department; and if he will make a statement on the matter. [8195/26]

246. Deputy Ken O'Flynn asked the Minister for Foreign Affairs and Trade if she will give a clear and unambiguous commitment to the House that Ireland will stand by its position regarding the EU–Mercosur trade agreement (details supplied); and if she will confirm that the Government recognises the wider significance of this case for other EU trade agreements, including CETA, where Ireland was given explicit assurances on sovereignty, democratic consent, and constitutional limits. [8871/26]

260. Deputy Ken O'Flynn asked the Minister for Foreign Affairs and Trade the process by which the Saint Brigid’s Day 2026 advertising and digital media campaign was commissioned by her Department; the officials or units involved in its commissioning and approval; the date on which final approval was given; and if she will make a statement on the matter. [9996/26]